{
     "PMID": "24917542",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20140826",
     "LR": "20170419",
     "IS": "1521-0103 (Electronic) 0022-3565 (Linking)",
     "VI": "350",
     "IP": "2",
     "DP": "2014 Aug",
     "TI": "Characterization of RO5126946, a Novel alpha7 nicotinic acetylcholine receptor-positive allosteric modulator.",
     "PG": "455-68",
     "LID": "10.1124/jpet.113.210963 [doi]",
     "AB": "Both preclinical evidence and clinical evidence suggest that alpha7 nicotinic acetylcholine receptor activation (alpha7nAChR) improves cognitive function, the decline of which is associated with conditions such as Alzheimer's disease and schizophrenia. Moreover, allosteric modulation of alpha7nAChR is an emerging therapeutic strategy in an attempt to avoid the rapid desensitization properties associated with the alpha7nAChR after orthosteric activation. We used a calcium assay to screen for positive allosteric modulators (PAMs) of alpha7nAChR and report on the pharmacologic characterization of the novel compound RO5126946 (5-chloro-N-[(1S,3R)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-b enzamide), which allosterically modulates alpha7nAChR activity. RO5126946 increased acetylcholine-evoked peak current and delayed current decay but did not affect the recovery of alpha7nAChRs from desensitization. In addition, RO5126946's effects were absent when nicotine-evoked currents were completely blocked by coapplication of the alpha7nAChR-selective antagonist methyl-lycaconitine. RO5126946 enhanced alpha7nAChR synaptic transmission and positively modulated GABAergic responses. The absence of RO5126946 effects at human alpha4beta2nAChR and 5-hydroxytryptamine 3 receptors, among others, indicated selectivity for alpha7nAChRs. In vivo, RO5126946 is orally bioavailable and brain-penetrant and improves associative learning in a scopolamine-induced deficit model of fear conditioning in rats. In addition, procognitive effects of RO5126946 were investigated in the presence of nicotine to address potential pharmacologic interactions on behavior. RO5126946 potentiated nicotine's effects on fear memory when both compounds were administered at subthreshold doses and did not interfere with procognitive effects observed when both compounds were administered at effective doses. Overall, RO5126946 is a novel alpha7nAChR PAM with cognitive-enhancing properties.",
     "CI": [
          "Copyright (c) 2014 by The American Society for Pharmacology and Experimental",
          "Therapeutics."
     ],
     "FAU": [
          "Sahdeo, Sunil",
          "Wallace, Tanya",
          "Hirakawa, Ryoko",
          "Knoflach, Frederic",
          "Bertrand, Daniel",
          "Maag, Hans",
          "Misner, Dinah",
          "Tombaugh, Geoffrey C",
          "Santarelli, Luca",
          "Brameld, Ken",
          "Milla, Marcos E",
          "Button, Donald C"
     ],
     "AU": [
          "Sahdeo S",
          "Wallace T",
          "Hirakawa R",
          "Knoflach F",
          "Bertrand D",
          "Maag H",
          "Misner D",
          "Tombaugh GC",
          "Santarelli L",
          "Brameld K",
          "Milla ME",
          "Button DC"
     ],
     "AD": "Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.). Roche Palo Alto, Palo Alto, California (S.S., T.W., R.H., H.M., K.B., M.E.M., D.C.B.); F. Hoffmann-La Roche AG, pRED, Pharma Research and Early Development, Discovery Neuroscience, Grenzacherstrasse, Basel, Switzerland (F.K., L.S.); gRED South San Francisco, California (D.M.); HiQScreen Sarl, Geneva, Switzerland (D.B.); and Psychogenics Inc., Tarrytown, New York (G.C.T.) dbutton@acorda.com.",
     "LA": [
          "eng"
     ],
     "GR": [
          "T32 GM099608/GM/NIGMS NIH HHS/United States"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20140610",
     "PL": "United States",
     "TA": "J Pharmacol Exp Ther",
     "JT": "The Journal of pharmacology and experimental therapeutics",
     "JID": "0376362",
     "RN": [
          "0 (5-chloro-N-(2,2-dimethyl-3-(4-sulfamoylphenyl)cyclopropyl)-2-methoxybenzamide)",
          "0 (Benzamides)",
          "0 (Receptors, GABA-A)",
          "0 (Receptors, Glutamate)",
          "0 (Sulfonamides)",
          "0 (alpha7 Nicotinic Acetylcholine Receptor)",
          "6M3C89ZY6R (Nicotine)"
     ],
     "SB": "IM",
     "MH": [
          "Allosteric Regulation",
          "Animals",
          "Benzamides/*pharmacology",
          "Cells, Cultured",
          "Cognition/drug effects",
          "Hippocampus/drug effects",
          "Humans",
          "Learning/drug effects",
          "Male",
          "Memory/drug effects",
          "Nicotine/pharmacology",
          "Rats",
          "Rats, Sprague-Dawley",
          "Receptors, GABA-A/physiology",
          "Receptors, Glutamate/physiology",
          "Sulfonamides/*pharmacology",
          "alpha7 Nicotinic Acetylcholine Receptor/*drug effects"
     ],
     "EDAT": "2014/06/12 06:00",
     "MHDA": "2014/08/27 06:00",
     "CRDT": [
          "2014/06/12 06:00"
     ],
     "PHST": [
          "2014/06/12 06:00 [entrez]",
          "2014/06/12 06:00 [pubmed]",
          "2014/08/27 06:00 [medline]"
     ],
     "AID": [
          "jpet.113.210963 [pii]",
          "10.1124/jpet.113.210963 [doi]"
     ],
     "PST": "ppublish",
     "SO": "J Pharmacol Exp Ther. 2014 Aug;350(2):455-68. doi: 10.1124/jpet.113.210963. Epub 2014 Jun 10.",
     "term": "hippocampus"
}